Today: 19 April 2026
DroneShield (ASX:DRO) share price jumps on COO hire as investors line up FY2025 results watch
10 February 2026
1 min read

DroneShield (ASX:DRO) share price jumps on COO hire as investors line up FY2025 results watch

Sydney, Feb 10, 2026, 17:43 AEDT — Market closed

  • DroneShield climbed 7.3% to finish at A$3.38, following the appointment of a new chief operating officer.
  • Michael Powell, who previously worked at Thales Australia, was brought in to oversee operations.
  • Market attention is turning to FY2025 results next week; calendars are marking Feb 19.

Shares of DroneShield Ltd jumped 7.3% to finish at A$3.38 on Tuesday after the Australian counter-drone firm tapped Michael Powell for the COO spot. The stock moved in a range from A$3.24 to A$3.39, with roughly 15.5 million shares traded, according to market data.

This is a crucial point for DroneShield: it’s not just about closing sales, but showing it can ramp up operations. Investors are eyeing delivery speeds, how many units roll off the line, and whether the company can match rising demand from defence and critical-infrastructure buyers.

Small, fast-growing defence suppliers know this drill: when orders hit, they’re often big, abrupt, and uneven. The challenge turns into ramping up inventory, hitting delivery windows, and managing costs as they go.

DroneShield announced Powell’s appointment after what it described as “accelerated expansion”—more happening across Europe and the US, plus added manufacturing muscle at its Alexandria, New South Wales site. In a statement, chief executive Oleg Vornik called Powell “a proven operator with deep experience delivering complex programs at global scale.” droneshield.com

Tuesday saw some renewed risk appetite, pushing the ASX 200 up slightly by mid-afternoon. Tech names bounced. DroneShield made the list of notable winners, according to IG market analyst Tony Sycamore.

Powell’s brief: keep production humming, supply chains tight, and prevent delivery or sustainment from slowing the expanding product line. DroneShield points to his 25-plus years in operational leadership, citing senior posts at Thales Australia and Knorr-Bremse.

Yet even with a new COO on board, major risks behind the stock’s volatility remain untouched. Shifting demand tracks with budget cycles and procurement schedules; plus, regulatory hurdles on some counter-drone “disruption” tools keep international sales complicated in key markets.

As Australia’s reporting season ramps up, traders have their eyes peeled for fresh numbers from the company. According to market calendars, DroneShield’s FY2025 results are penciled in for Feb 19, but those dates aren’t set in stone.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 10.02.2026

SGX stock price today: Singapore Exchange shares edge up after January trading surge
Next Story

SGX stock price today: Singapore Exchange shares edge up after January trading surge

Go toTop